Alternative splicing of the pituitary adenylate cyclase-activating polypeptide receptor PAC1: mechanisms of fine tuning of brain activity

Janna Blechman and Gil Levkowitz *
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

INTRODUCTION

G-protein-coupled receptors (GPCRs) represent the largest family of membrane-associated proteins mediating physiological responses in vertebrates by means of controlling metabolic, neural, and developmental functions (Lefkowitz, 2007; Frooninckx et al., 2009; Hoyer and Bartfai, 2012; Jafurulla and Chattopadhyay, 2013). These proteins are expressed in almost all types of tissues and are represented by over 1,000 membrane receptors for extracellular (EC) ligands including hormones, neurotransmitters, pheromones, lipids, and other proteins (Xue et al., 2008; Markovic and Grammatopoulos, 2009; Nordstrom et al., 2009; Hoyer and Bartfai, 2012; Jafurulla and Chattopadhyay, 2013). The basic structure of GPCR proteins consists of a seven-transmembrane (TM) domain with a complex EC structure composed of an N-terminal region and three EC loops involved in the diverse ligand recognition process. Three intracellular (IC) loops and a C-terminal domain transduce a signal into the cell’s cytoplasm and nucleus. Typically, ligand binding to the EC loops induces conformational changes in the TM and IC domains of the receptor resulting in specific coupling to a set of cytoplasmic molecules, termed G-proteins, each composed of different isoforms of alpha, beta, and gamma subunits. G-proteins in turn regulate the activity of IC effector molecules, including adenylate cyclase (AC), phospholipase Cβ (PLC), and RhoGEF causing the activation of secondary messengers such as cyclic AMP (cAMP), inositol-1,4,5-trisphosphate (InP3), and diacylglycerol leading to the initiation of distinct IC signaling pathways (Simon et al., 1991; Sah et al., 2000; Pierce et al., 2002; Oldham and Hamm, 2008; Mizuno and Itoh, 2009; Mahata et al., 2011; Maurice et al., 2011).

The diversity of the GPCR-initiated signal transduction pathways is determined by the multiplicity of cognate ligands with different receptor binding properties and by the receptors’ membrane-interacting partners that form homo- and hetero-dimerized GPCR complexes. These receptor dimers have unique binding properties to both EC ligands and a set of IC G-proteins (Milligan and Kostenis, 2006; Harikumar et al., 2008; Furness et al., 2012). Thus, ligand binding, along with receptor heterodimerization, can generate diversity in G-proteins coupling that can generate varied IC signaling functions.

Beyond the complexity of the aforementioned EC and IC GPCRs interacting effectors, the genetic diversity of the GPCR family can be generated by means of alternative precursor mRNAs (pre-mRNA) splicing of exons encoding specific protein moieties and causing considerable functional differences of the resulting splicing products (Black, 2003; Jaillon et al., 2008; Furness et al., 2012). Alternative splicing mechanisms allow the generation of multiple mRNA transcript variants from a single gene by utilizing different combinations of exons by means of skipping or insertion of alternatively spliced exons. In particular, neuronal cells are known to exhibit high levels of alternative splicing, generating the basis for molecular and cellular diversity important for the patterning and maintenance of the central and peripheral nervous systems (Yeo et al., 2007; Betke et al., 2012; Norris and Calarco, 2012; Sun et al., 2012). In the case of GPCRs, this combinatorial exon assembly can lead to changes in the protein domains responsible for ligand binding, IC effector coupling, as well as receptor stability, and endocytosis.

In this review we focus on one GPCR, the pituitary AC-activating polypeptide (PACAP) receptor (ADCYAP1R1), also known as PAC1. This receptor represents a fascinating example of how alternative splicing of a single GPCR gene leads to different physiological outcomes. We will describe the current knowledge regarding the role and mechanism of action of PAC1 splice variants in development, physiology, and diseases focusing on PAC1’s role in the nervous system.
THE PAC1 RECEPTOR

PAC1 belongs to the glucagon/secretin receptor family of GPCRs that consists of hormone and neuropeptide receptors. These receptors signal through coupling to the G-protein alpha subunits Gs and Gq that typically activate AC and phospholipase Cβ enzymes, respectively (McCulloch et al., 2002; Ahren, 2008; Dickson and Finlayson, 2009; Vallejo, 2009; Vaudry et al., 2009). Coupling of PAC1 to Gs may also lead to cAMP-dependent accumulation of IC calcium (Braas and May, 1996; Mustafa et al., 2010). The PAC1 gene contains multiple exons that undergo extensive alternative splicing. The peptide PACAP is the high-affinity ligand for PAC1. Post-translational proteolytic processing of the PACAP precursor protein generates several polypeptides with varying sizes, including PACAP38 and PACAP27 (Miyata et al., 1989; Vaudry et al., 2009; Harmar et al., 2012; Watkins et al., 2012). PAC1 was found to play a pivotal role in the spatio-temporal regulation of proliferation, differentiation, or cell survival during development as well as in the regulation of synthesis and release of neuroendocrine hormones.

Phylogenetic analysis of the vertebrate PAC1 receptor family indicates their origin from a common ancestral gene and demonstrates a tree topology with species-specific paralogs belonging to different separated sub-groups (Figure 1). Bony fishes (teleosts) genomes typically contain more than one gene due to teleost-specific gene duplication event of both ligand and receptor molecules during the evolution of these species (Wei et al., 1998; Fradinger et al., 2005; Bjarnadottir et al., 2006; Cardoso et al., 2007; Machluf et al., 2011).

ALTERNATIVELY SPliced PAC1 GENE PRODUCTS

The alternative splicing of PAC1 has been extensively studied. In this review we use the exon numbers designation of the human PAC1 and otherwise indicate cases where the exons numbers do not match. The human gene was shown to contain 18 exons with the open reading frame encoded by exons 2–18 (Chatterjee et al., 1997; Lutz et al., 2006). Ten of these exons are constitutively expressed (exons 2, 3, 7–13, 18), whereas the rest (exons 4–6, 14, 15, and possibly 16, 17) are regulated by the alternative splicing (Figure 2). The N-terminal part of PAC1’s EC domain is encoded by six exons. Exons 7–17 encode the seven-TM domains including EC and IC loops and exon 18 encodes the C-terminal cytoplasmic tail including the 3′-untranslated region (Figures 2 and 3). PAC1 splicing variants were identified in other vertebrate species including rat, mouse, frog, and fish. In Table 1 we assembled all known PAC1 splice isoforms from different vertebrate species. The functional outcome of these splicing events will be discussed later. By and large, PAC1 alternative splicing can be divided into four types of splicing events that impact receptor functions (Figure 3; Table 1): (1) Variations in the EC N-terminal domain altering the ligand-binding specificity and affinity. (2) Variations in exons encoding to part of the third IC loop (IC3) thereby affecting G-protein coupling and/or interaction with other IC signaling proteins. (3) Variations in the TM domains TM2 and TM4 contributing to the receptors heteromerization and IC transport. (4) Variations in the 5′ UTR that may affect mRNA expression dynamics. Notably, splicing products containing different combinations of N-terminal and IC3 splice variants were identified in mammalian species.

The terminology used in independent studies can be somewhat perplexing as different names were designated to PAC1 isoforms corresponding to the same splicing events identified in various species. In the following section we describe the various splice variants and indicate when a different (i.e., specie-specific) name was designated to the same isoform. A splice isoform that includes all N-terminal encoding exons but does not contain IC (IC3) insertion(s) is referred to as “PAC1-null” (Table 1). The ligand binding and signaling properties of PAC1-null are often used as a reference when assessing the activities of other splice variants.

N-TERMINAL VARIATIONS

The N-terminal variants were identified in rodents and humans but not in fishes to date. They are generated by alternative splicing of exon 5 (PAC1-δ5), exons 5–6 (PAC1-short or PAC1-δ5,6), or exons 4–6 (PAC1-very short or PAC1-δ4,5,6) leading to deletions of 7, 21, or 57 amino acids, respectively (Journot et al., 1994;
INTRACELLULAR LOOP VARIATIONS

PAC1 splice variants in the third IC loop (IC3) have been identified in human, amphibian, fishes, and rodents. These splice isoforms are characterized by the presence of one or two cassettes of 84 nucleotides (hip or hop1 variants) or 81 nucleotides (hop2 variant), or a combination of alternative spliced "cassettes" (hip-hop1 or hip-hop2) (Spengler et al., 1993; Journot et al., 1995; Grimaldi and Cavallaro, 1999; McCulloch et al., 2001; Ronaldson et al., 2002; Fradinger et al., 2005; Ushiyama et al., 2007; May et al., 2010; Holighaus et al., 2011). In human, hip and hop variants are also referred to as SV1 and SV2 or SV3 for hip-hop1 (Pisegna and Wank, 1996; Pisegna et al., 1996). In addition, a splice variant formed by a C-terminal deletion of 193 nucleotides (denoted "hop1 novel") including two amino acids that are essential for G-protein recognition was identified in rat cochlea samples (Abu-Hamdan et al., 2006). Similar alternative splicing variants of PAC1 are also found in non-mammalian vertebrates such as the frog and bony fishes. Three alternative splice variants were identified in the frog IC3 loop (Alexandre et al., 2002). PAC1-R25, with an insertion of 25 amino acids, corresponds to the mammalian hop cassette. PAC1-R41 contains a cassette with no homology to any other variant. PAC1-RMc with a unique cytoplasmic insertion of 13 amino acids into the TM7 domain is missing a canonical Gs recognition motif. PAC1 genes were also identified in zebrafish, goldfish, stickleback, fugu, sea bream, and several others bony fish species. Three zebrafish PAC1 alternative splice variants with insertions in the IC3 loop were identified. Two of them were found to be homologous to the hop1 (84 nucleotides) and hop2 (81 nucleotides) mammalian isoforms (Fradinger et al., 2005). A unique 107 nucleotides inclusion with a premature stop codon (PAC1-skip) resulting in a truncated PAC1 protein did not correspond to any previously detected PAC1 isoform (Fradinger et al., 2005). This isoform resembles an alternative splicing event in a human gene encoding another secretin family receptor, VPAC1. Interestingly, the hip cassette variant was not identified in the mouse and zebrafish genomes. Moreover, teleosts genomes contain two (duplicated PAC1 paralogs, pac1a and pac1b, however, only pac1a encodes for the hop splicing cassette.

TRANSMEMBRANAL DOMAIN VARIATIONS

A PAC1 variant, cloned from the rat cerebellum, has amino acids deletion/substitution in the TM4 domain along with two amino acid substitutions in the N-terminal (D136N) and TM2 (N190D) domains (Chatterjee et al., 1996; Ajpru et al., 2002). The exact molecular mechanism underlying these variations remains unclear. Notably, the TM4 domain of the secretin family receptors are involved in homo- and hetero-oligomerization of these receptors, associations with receptor activity-modifying proteins (RAMPs), and with GPCR kinases (GRKs) thereby suggesting that splice alterations in the PAC1-TM4 domain may affect receptor function (Morfis et al., 2003; Ritter and Hall, 2009; Magalhaes et al., 2012).

5′ UTR VARIATIONS

Alternative splicing events in exons located at the 5′ UTR were identified for rat PAC1 gene (Chatterjee et al., 1997). These include different alternative usage of exons located upstream to the ATG translation start codon. Such variations in the 5′ UTR organization and sequences may play a role in the regulation of mRNA expression.

ALTERNATIVE PAC1 SPLICING ALTERS LIGAND-BINDING PROPERTIES

PAC1 is considered as being the high-affinity receptor for PACAP, while it displays low binding affinity to the vasoactive intestinal polypeptide (VIP) (Apostolakis et al., 2005; Vaudry et al., 2009; Harmar et al., 2012). Alternative splicing of PAC1 results in different protein products displaying different ligand-binding properties that may result in changes in affinity and selectivity (Table 1). Most studies use the PAC1-null (McCulloch et al., 2001; Holighaus et al., 2011) isoform as a reference for PACAP and VIP binding properties.

Modeling of ligand-receptor binding proposes that the C-terminal part of the ligand PACAP binds to the N-terminus of the PAC1 receptor and that the N-terminal part of PACAP binds to the receptor’s EC loops and TM domains (Furness et al., 2012). Consequently, alterations in the EC domain of PAC1 are predicted to affect these ligand-receptor binding properties (Table 1). Thus, PAC1-very short (a.k.a. PAC1-s4,5,6), which lacks 57 amino acids in the EC1 domain displays decreased affinity to PACAP27 and PACAP38 but its affinity toward VIP remains the same (Journot...
Table 1 | Biochemical properties of PAC1 splice variants.

| PAC1 isoforms | Species | Sequence alterations | Binding properties | Signaling consequences | Reference |
|---------------|---------|---------------------|--------------------|------------------------|-----------|
| null          | rat, human, mouse, zebrafish | PAC1 containing exons 2–13, 16–18 | Pacap38 ≈ Pacap27 > VIP, Pacap38 > Pacap27 > VIP* | PIP3 turnover | Spengler et al. (1993), Wei et al. (1998), Grumolato et al. (2003), Fradinger et al. (2005), Lutz et al. (2006), Ushiyama et al. (2007, 2010), Chafai et al. (2011), Holighaus et al. (2011) |
| hop1          | rat, mouse, human* | Insertion of exon 15 into IC3 loop | Pacap38 ≈ Pacap27 > VIP, Pacap38 ≤ Pacap27 < VIP* | PIP3 turnover | Spengler et al. (1993), Pisegna and Wank, 1996, Pisegna et al. (1996), McCulloch et al. (2002), Ronaldson et al. (2002), Mustafis et al. (2007), May et al. (2010), Holighaus et al. (2011) |
| hop1 novel    | rat      | 193 bp deletion: TM6, EC3 loop, TM7, and part of C-terminal tail | Pacap38 ≈ Pacap27 > VIP, Ser417 are essential for G-protein coupling | No activation | Abu-Hamdan et al. (2006) |
| hop2          | rat, zebrafish* | Insertion of exon 15 into IC3 loop | Pacap38 ≈ Pacap27 > VIP, Pacap38 < Pacap27 < VIP | PIP3 turnover | Spengler et al. (1993), Cavallaro et al. (1995), Wei et al. (1998), Grimaldi and Cavallaro (1999), Pilzer and Gozes (2006b) |
| hip           | rat, human* | Insertion of exon 14 into IC3 loop | Low affinity Pacap38 ≈ Pacap27 > VIP | PIP3 turnover | Spengler et al. (1993), Journot et al. (1995), Pisegna and Wank, 1996, Pisegna et al. (1996), Ronaldson et al. (2002), Germano et al. (2004), Lutz et al. (2006) |

(Continued)
| PAC1 isoforms | Specie alterations | Binding properties | AC activation (Gs) cAMP production | PLC stimulation (Gq) IP3 turnover | Ca\(^{2+}\) mobilization from intracellular and extracellular stores | Reference |
|----------------|---------------------|---------------------|-----------------------------------|----------------------------------|-------------------------------------------------|-----------|
| hip-hop SV3*  | rat, human*         | Insertion of exons 14, 15 into IC3 loop | Pacap38 ≈ Pacap27 > VIP | Pacap38 ≈ Pacap27 > VIP | Pacap38 > Pacap27 > VIP | No Ca\(^{2+}\) influx ND* | Spengler et al. (1993), Pisegna and Wank, 1996, Pisegna et al. (1996), Lu et al. (1998), Abu-Hamdan et al. (2006) |
| short \#5,6* | rat, mouse, human*  | Deletions of exons 5,6 | Pacap38 ≈ Pacap27 > VIP | Pacap38 > Pacap27 > VIP | Pacap38 > Pacap27 > VIP | Pacap38 > Pacap27 > VIP | Pantaloni et al. (1996), Dautzenberg et al. (1999), Lutz et al. (2006), Ushiyama et al. (2007, 2010) |
| short hop1 \#5,6 hop1* | rat, mouse, human* | Deletions of exons 5,6, insertion of exon 15 | Pacap38 ≈ Pacap27 > VIP | Pacap38 > Pacap27 > VIP | Pacap38 > Pacap27 > VIP | Pacap38 > Pacap27 > VIP | Dautzenberg et al. (1999), Lutz et al. (2006), Ushiyama et al. (2007, 2010) |
| \#5,6-hip | human | Deletions of exons 5,6, insertion of exon 14 | Pacap38 ≈ VIP | Pacap38 > VIP | Pacap38 > VIP | Pacap38 > VIP | Lutz et al. (2006) |
| very short \#4,5,6* | rat, human* | Deletions of exons 4,5,6 | Low affinity Pacap38 ≈ Pacap27 > VIP | Low potency Pacap38 > Pacap27 > VIP | No activation ND | Pacap38 > Pacap27 > VIP* | Pantaloni et al. (1996), Dautzenberg et al. (1999), Lutz et al. (2006) |
| 3a | rat | N-terminal insertion of exon 3a (72 bp) | Sixfold increased affinity to Pacap38 | Reduced sensitivity to Pacap38; Pacap27 like null | Reduced sensitivity to Pacap38 and Pacap27 | Pacap38 and Pacap27 stimulate Ca\(^{2+}\) like V null | Daniel et al. (2001), Ajpru et al. (2002), Pilz and Gozes (2006b) |
| Pac-TM4 | rat | TM4-deletion/insertion (12 to 6 bp), TM2 -D136N in EC1, N190D | Pacap38 ≈ Pacap27 | Low potency (BNK cells) Pacap27 > VIP; no activation (CHO cells) | Low potency (BNK) Pacap27 > VIP; no activation (CHO) | Pacap27 via activation of dihydropyridine-sensitive L-type Ca\(^{2+}\) channels | Chatterjee et al. (1996), Ajpru et al. (2002) |
| PAC1 isoforms | Species | Sequence alterations | Binding properties | Signaling consequences | Reference |
|--------------|---------|---------------------|--------------------|-----------------------|-----------|
| δ5 human     | Deletion of exon 5 | ND | P
cap38 > P
cap27 > VIP | No activation | Lutz et al. (2006) |
| δ5 hop1 human | Deletion of exon 5, insertion of exon 15 | ND | P
cap38 > P
cap27 > VIP | No activation | Lutz et al. (2006) |
| δ5 hip human  | Deletion of exon 5, insertion of exon 14 | ND | P
cap38 ≥ VIP | No activation | Lutz et al. (2006) |
| δ5,6,14–17 human | Deletion of exons 5,6, deletion/inclusion in TM6, EC3 & EC4 | ND | P
cap38 ≥ VIP | No activation | Fadinger et al. (2005) |
| skip zebrafish | Insertion into the IC3 loop with premature stop codon | ND | ND | No activation, loss of G-protein coupling site | ND |
| R25 frog     | Insertion of a hop-like cassette into the IC3 loop | ND | P
cap38 > VIP | No activation | Alexandre et al. (2002) |
| R41 frog     | Insertion into the IC3 loop | ND | P
cap38 > VIP | No activation | Alexandre et al. (2002) |
| Rmc frog     | Insertion into TM7 C-term. | ND | P
cap38 > VIP | Loss of a positive PKC phosphorylation site | ND |

*Information relating to biochemical properties obtained in specific vertebrate species are marked by the asterisk symbol.
et al., 1995; Pantaloni et al., 1996; Dautzenberg et al., 1999; Lutz et al., 2006). The binding affinities for PACAP38 of the $\delta_5$, $\delta_5,6$ (a.k.a. short) splice isoforms appeared to be very similar to that of PAC1-null, while $\delta_5,6$ isoform has increased affinity toward VIP. The rat-specific PAC1-3a isoform containing a 24 residue N-terminal insertion displays increased affinity to PACAP38 but not to PACAP27 (Daniel et al., 2001; Pilzer and Gozes, 2006a). It should be noted that in all of these examples, PACAP is still the better ligand for PAC1 when compared with VIP (Table 1).

The hop1 and hip-hop1 splice isoforms retain similar binding properties to those of PAC1-null. In contrast, insertions into the IC3 loop, namely hip- and hop2-cassettes lead to the elevation of VIP (Spengler et al., 1993; Pisegna et al., 1996; Pilzer and Gozes, 2006b) and the diminution of PACAP binding affinities, thereby suggesting that the alteration in IC3 causes an inside-out conformational change.

Notably, binding analysis of alternative spliced isoforms, which result from combined changes in the EC and IC protein domains yields interesting results. Thus, a splice variant composed of PAC1-short with the inclusion of hop1-cassette, displays similar PACAP and VIP binding properties to that of PAC1-null and different VIP binding properties than PAC1-short alone (Lutz et al., 2006; Ushiyama et al., 2007, 2010). Another combined splice variant composed of PAC1-$\delta_5$ or PAC1-$\delta_5,6$ together with the hip cassette had different ligand-binding properties to that of PAC1, PAC1-$\delta_5$, or PAC1-hip alone (Lutz et al., 2006) (Table 1). This imply that the IC3 domain contributes to the association of PAC1 with its cognate ligands.

These results may be explained by a model for agonist binding to the corticotropin-releasing hormone (CRH) receptor, which belongs to the same GPCR sub-family of PAC1 (Dong et al., 2005). According to this model the TM6 protein domain plays a structural role in ligand binding. Thus, insertions into IC3 loop, which is located between TM5 and TM6 region may cause a conformational change in TM6 and possibility affect binding of PACAP and VIP to the EC part of the receptor. A proof for this model awaits a solved three-dimensional protein structural of the different PAC1 isoforms.

**ALTERNATIVE PAC1 SPLICING ALTERS INTRACELLULAR SIGNAL TRANSDUCTION**

Ligand binding to PAC1 results in allosteric changes in the IC docking sites for effector coupling. A variety of IC signal transduction cascades can be differentially transduced by multiple PAC1 splice variants with altered EC or IC protein domains (Figure 4) (Arimura, 1998; Dickson and Finlayson, 2009; Vaudry et al., 2009; Furness et al., 2012). The most studied pathways include coupling of PAC1 to $G_s$ and $G_q$ proteins and activation of AC and phospholipase C (PLC) which result in the respective stimulation of production of cAMP and/or IP3 (Milligan and Kostenis, 2006;
FIGURE 4 | A scheme depicting the current knowledge on PAC1-mediated signaling cascades resulting in a variety of neuronal outcomes. PKA was shown to induce ERK1/2 thereby contributing to PACAP neuroprotective (Villalba et al., 1997; Vaudry et al., 2003; Falluel-Morel et al., 2006; Stumm et al., 2007) and neurotrophic (Flavin et al., 2006; Bota et al., 2007; Monaghan et al., 2008) functions. Action potential (AP) firing induces a CRECT1/CREB-mediated neuroprotective effect, presumably through NMDA receptor activation and was shown to be initiated by PKA activation (Baxter et al., 2011). NMDA receptor was also shown to be indirectly activated by PACAP (Llansola et al., 2004) or cAMP/PKA signaling (Costa et al., 2009). PAC1/PKA signaling controls cellular apoptosis through inhibition of potassium channels (Mei et al., 2004; Castel et al., 2006; Pugh and Margiotta, 2006) or induction of calcium channels (Pugh and Margiotta, 2006). PAC1/PKA-mediated activation of ion channels leads to activity-dependent neuronal differentiation and synaptic plasticity (Lee et al., 1999; Maturana et al., 2002; Grumolato et al., 2003; Nishimoto et al., 2007). The tumor suppressor gene Lot1 known as a negative regulator of neuronal precursor proliferation was shown to be controlled by PAC1/cAMP/ERK signaling pathway (Fila et al., 2009). PAC1/PKA-dependent phosphorylation of Tau is involved in the control of granule cell migration during cerebellar development (Falluel-Morel et al., 2006). PAC1-mediated cAMP/ERK-dependent neurite outgrowth was shown to be regulated via a novel neurogenic factor NCS (Emery and Eiden, 2012) or Epac/ERK (Gerardin and Eiden, 2007) pathways. PAC1/Epac was shown to regulate neuronal differentiation via activation of p38 kinase along with mobilization of Ca2+ from intracellular stores (Etier et al., 2007) as well as Epac/Rit-dependent pathway involving CREB signaling (Shi et al., 2006). PAC1 was shown to be induced by Rit through TRKA/Shc/SOS signaling initiated by Src activation via dual Ga/Epac and Gi stimulation (Shi et al., 2010). PACAP also signals through Gq-linked PLC > IP3 > Ca2+/DAG > PKC, and PLD > phosphatidic acid (PA) pathways (Journot et al., 1994; Makhoul and Murthy, 1997; Deja et al., 2006). PAC1 is a mediator of gene transcription, neuronal differentiation, and synaptic development (Masmoudi-Kouki et al., 2006; Vaudry et al., 2007; Andero and Reseler, 2013). As an example of functional diversity caused by PAC1 alternative splicing two additional PAC1-hop1 signaling pathways are presented on the scheme. They depict PAC1-hop1/ARF-dependent PLD activation (McCulloch et al., 2001) and internalization-dependent engagement of PI3K/Akt activation (May et al., 2010). AC, adenylyl cyclase; AGS, activator of G protein signaling; Akt, serine/threonine protein kinase PKB; cAMP, cyclic adenosine monophosphate; ARF, ADP(adenosine diphosphate) ribosylation factor; Caln, calcineurin; CaMK, calcium calmodulin kinase; CBP, creb binding protein; CREB, cAMP responsive element-binding protein; DAG, diacyl glycerol; Epac, exchange factor directly activated by cAMP; ERK, extracellular signal-regulate kinase; G, guanine nucleotide-binding regulatory protein; IP3, inositol-1,4,5-triphosphate; JNK, c-Jun oncogene N-terminal kinase; Lot1, lost on transformation 1; NCS, neurogenic cAMP sensor; NMDA, N-methyl-d-aspartate receptor; p38, p38 mitogen-activated protein kinase; PA, phosphatidic acid; PI3K, phosphatidylinositol 3′ OH kinase; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase; Rit, Rit, small GTPases of the RAS oncogene family; Sos, son of sevenless homolog 1; Src, sarcoma viral oncogene homolog; Tau, neuron-specific microtubule-associated protein; TrkA, tropomyosin-related kinase.

Couvineau and Laburthe, 2012) (Figures 3 and 4). In addition, PAC1 was shown to regulate the level of IC Ca2+ in either G-protein dependent or independent manners. The following section reviews the role of PAC1 splice variants in the activation of the above pathways as well as other non-canonical signalling cascades (see also Table 1).
AC AND PLCβ
When compared to the PAC1-null isoform, some alternative splice variants display altered mode of signaling. For example, PAC1 isoform 3a, 5,4,5,6 (a.k.a. very short), hop, hop-hop, 5-hip, and 5,6,6-hop show reduction in the potency of agonists-mediated cAMP and IP3 production (Spengler et al., 1993; Dautzenberg et al., 1999; Parsons et al., 2000; Daniel et al., 2001; Germano et al., 2004; Lutz et al., 2006; Pilzer and Gozes, 2006a; Holighaus et al., 2011). Similarly, PAC-TM4, hop1 novel, 5,6,14–17, skip, and Rmc have lost their ability to stimulate cAMP and IP3 production (Chatterjee et al., 1996; Daniel et al., 2001; Aipru et al., 2002; Alexandre et al., 2002; Fradinger et al., 2005; Abu-Hamdan et al., 2006; Pilzer and Gozes, 2006a). Notably, all of the above splice variants have modified or deleted IC3, TM, and C-terminal protein domains that are known to be important for G-protein binding (Chatterjee et al., 1996).

In some studies, PAC1-null displays very low or no activation of PLCβ while PAC1-hop1 switches its mode of signaling from AC to PLCβ (Spengler et al., 1993; DiCicco-Bloom et al., 2000; Nicot and DiCicco-Bloom, 2001; Ronaldson et al., 2002; May et al., 2010). For example, PAC1-hop1 was reported to mediate the activation of both AC and phospholipase C signaling in cortical sympathetic neuroblasts, while PAC1-null merely signals via AC stimulated pathway (Braas and May, 1996; DiCicco-Bloom, 2000). Other studies report that both isoforms display dual activation of AC and PLCβ pathways, however the hop1 isoform has higher activation of these pathways. Thus, analyses of SV1/hip and SV2/hip show that these isoforms display increased coupling to cAMP and PLCβ, respectively (Spengler et al., 1993; Pisegna and Wank, 1996; Lu et al., 1998; Braas and May, 1999; Parsons et al., 2000; Nicot and DiCicco-Bloom, 2001; Germano et al., 2004; Lutz et al., 2006; May et al., 2010; Holighaus et al., 2011). The frog R25 and R41 isoforms containing amino acid insertions into IC3 have higher activation of AC and PLCβ compared to PAC1-null (Alexandre et al., 2002).

Consistent with the effect of IC3 loop insertions on ligand-binding properties, hip- and hop2-cassettes conferred comparable potency to induction of cAMP and IP3 accumulation by PACAP and VIP but at the same time characterized by much lower efficacy of this response (Spengler et al., 1993; Pisegna and Wank, 1996; Pisegna et al., 1996; Ronaldson et al., 2002; Lutz et al., 2006). On the other hand, PAC1-hop variant was shown to retain AC mediated signaling but demonstrated impaired coupling to the PLCβ pathway (May et al., 2010).

CA2+ SIGNALING
The concentration of calcium ions (Ca2+) in the cytoplasm is controlled by its uptake and release by specific transporter proteins residing in the plasma membrane, the inner mitochondria membrane, and the endoplasmic reticulum (ER) (Clapham, 2007). PAC1-mediated Ca2+ signaling was shown to play important roles in regulating neurotransmitter release, and neurotransmitter receptors (Shioda et al., 1997; Taupenot et al., 1999; Germano et al., 2009; Mustafa et al., 2010; Pugh et al., 2010; Amir-Zilberstein et al., 2012; Smith and Eiden, 2012). The effects of PAC1 splice isoforms on the levels of cytoplasmic Ca2+ were reported in the cases of PAC1-null hop1/2, 5,6/short, 3a, and PAC1-TM4 (Table 1) (Dautzenberg et al., 1999; Lutz et al., 2006; Mustafa et al., 2007, 2010; Nishimoto et al., 2007; Germano et al., 2009; Hansson et al., 2009; Vallejo, 2009; Ushiyama et al., 2010; Holighaus et al., 2011). PACAP is known to modulate both EC Ca2+ influx via voltage-gated calcium channels (VGCC) and Ca2+ release from IC ER stores through both IP3/PLCβ and AC pathways but also through other signaling cascades (Tanaka et al., 1997; Shioda et al., 1998; Grimaldi and Cavallaro, 1999).

PAC1-null was reported to modulate cytosolic Ca2+ mobilization from both EC and IC stores (Shioda et al., 1997; Masmoudi et al., 2003; Payet et al., 2003; Nishimoto et al., 2007). In acutely dissociated rat melanotrophs, the increase of cytosolic Ca2+ was dependent on the activation of non-selective cation channels and the facilitation of voltage-dependent Ca2+ channels by PKC- and PKA-dependent phosphorylation, respectively (Tanaka et al., 1997). cAMP-dependent entry of EC calcium was also reported in astrocyte cells (Vallejo, 2009). It was also suggested that PAC1-null-mediated elevation of cytoplasmic Ca2+ levels in NG108-15 cells is due to IP3 receptor-mediated Ca2+ release from IC stores (Holighaus et al., 2011).

The PAC1-hop1 variant is responsible for both Ca2+ mobilization from IC stores and influx through voltage-gated Ca2+ channels in bovine chromaffin cells (Mustafa et al., 2007). Transfection of PAC1-hop to the adrenomedullary pheochromocytoma (PC12) cell line showed sustained IP3-mediated Ca2+ release from IC stores and from store-operated Ca2+ entry (SOCE) (Taupenot et al., 1999; Mustafa et al., 2007, 2010). In bovine adrenal chromaffin cells, PAC1-hop was shown to mediate cytosolic Ca2+ release from ryanodine/caffeine-sensitive Ca2+ stores that was not dependent on either cAMP or IP3 generation (Tanaka et al., 1998; Payet et al., 2003). Heterologous expression of the rat PAC1-hop1 but not PAC1-hop1 variant in NG108-15 and PC12 cells leads to an increase in IC Ca2+ concentration (Mustafa et al., 2007; Holighaus et al., 2011). In both cell lines the response consisted of a rapid and transient rise of Ca2+ reminiscent of IP3 receptor-mediated Ca2+ release from IC stores followed by a prolonged Ca2+ accumulated from EC source.

When compared with PAC1-null, PAC1-hop1 was more potent in Ca2+ elevation (Holighaus et al., 2011). However, following overexpression in Chinese Hamster Ovarian cells, activation of PAC1-null induced higher Ca2+ levels when compared with activation of PAC1-hop1 (Ushiyama et al., 2010). PAC1-hop1 also mediated PACAP-induced Ca2+ release from ER and PKCγ translocation to the nucleus and plasma membrane resulting in the astrocytic differentiation (Nicot and DiCicco-Bloom, 2001). Finally, stimulation of voltage-gated L-type or non L-type Ca2+ channels following initiation of PAC1-hop1 signaling was also reported (Mustafa et al., 2010).

Somewhat limited data was reported with regards to Ca2+ signaling via other PAC1 splice variants. Thus, δ5,6/short as well as the PAC1 isoform containing combined "short" deletion in the N-terminal EC1 domain along with hop1-cassette in the IC3 loop exhibit PACAP-induced cytoplasmic calcium elevation (Ushiyama et al., 2010). PAC1-3a was shown to induce Ca2+ accumulation through coupling to Gs/cAMP rather than Gq/PLCβ pathway (Pilzer and Gozes, 2006a). PAC1-TM4 that was found to be inactive when assayed for both cAMP and PLCβ activation but it displayed elevation of Ca2+ in response to PACAP27. It was demonstrated
that this effect involved the modulation of voltage-gated L-type Ca\(^{2+}\) channels (Chatterjee et al., 1996).

Taken together, the apparent inconsistent results concerning the mechanisms underlying the aforementioned Ca\(^{2+}\) signaling events are most likely due to the different cellular systems (e.g., cell types) employed by the above studies to analyze PAC1-mediated IC Ca\(^{2+}\) changes.

OTHER TRANSDUCTION PATHWAYS

Signaling of PAC1 through interaction with cytoplasmic protein partners, other than the canonical Gs and Gq, was reported mainly in the case of the PAC1-hop1 isoform (McCulloch et al., 2001; Ronaldson et al., 2002). Both PAC1-null and -hop1 proteins were reported to activate phospholipase D (PLD). Although PAC1-null-mediated PLD stimulation involved Gq/11 > PLC > PLD pathway, PAC1-hop1 was capable of activating PLD through direct binding to ADP-riboseylation factor (ARF) (McCulloch et al., 2002; Dejda et al., 2006).

EXPRESSION OF PAC1 SPLICE ISOFORMS IN THE NERVOUS SYSTEM

Information on time- and region-specific distribution of PAC1 splice isoforms may shed light on how PAC1 gene products regulate a plethora of biological functions in developmental and physiological processes (D’Agata et al., 1996; Waschek et al., 2000; Waschek, 2003; Vaudry et al., 2009). The distribution of PAC1 has been examined in many species using different techniques that revealed widespread expression in different tissues, including the nervous, cardiovascular, endocrine, immune, and respiratory systems (Aino et al., 1995; Abu-Hamdan et al., 2006; Gomariz et al., 2006; Molnar et al., 2008; Jolivel et al., 2009; Shneider et al., 2010; Lugo et al., 2011; Buljan et al., 2012). However, knowledge concerning the expression of PAC1 splice variants is somewhat limited at it is mainly based on analyses of isolated brain areas and/or primary cell cultures. The reported changes in PAC1 receptor variant expression appear to be most evident during development. We have summarized the existing data concerning the expression of these variants by focusing on expression in the nervous system of different mammalian species.

The major mRNA isoform of PAC1 in the brain is PAC1-null, which contains no splice deletions or insertions. PAC1-null is predominantly expressed in neurons residing in different brain areas although it is also detected in glial cells of the cerebella cortex and in activated astrocytes (Pilzer and Gozes, 2006b; Dickson and Finlayson, 2009; Vaudry et al., 2009).

PAC1 variants with N-terminal deletions are well represented in human fetal brain tissues and in five human neuroblastoma lines (Lutz et al., 2006; Falktoft et al., 2009), thereby suggesting their role in immature nervous tissue. N-terminal splice variants were detected in different brain areas. The PAC1-short variant with 21 amino acids N-terminal deletion was predominantly found in the thalamus, hypothalamus, and the hypophysis, and more moderately in the amygdala and retina (Dautzenberg et al., 1999; Grimaldi and Cavallaro, 1999; Jämen et al., 2002; Girard et al., 2004; Lutz et al., 2006; Ushiyama et al., 2007, 2010; Hammack et al., 2010a). It was shown to be expressed in cochlea subfractions along with the PAC1-55 isoform with a seven amino acid deletion (Abu-Hamdan et al., 2006). The PAC1-very short variant (57 amino acid deletion) was also detected at low levels in the mouse amygdala and cortex though not in the retina. All three N-terminal variants (null, short, and very short) were abundantly expressed in neuronal tissues (Dickson and Finlayson, 2009; Vaudry et al., 2009). The PAC1-3a variant containing N-terminal insertion of 24 amino acids was detected in rat cerebral cortex. This splice isoform is also highly expressed in distinct cell populations of the testis, including Sertoli cells, pachytene spermatocytes, and round spermatids (Daniel et al., 2001; Ajpru et al., 2002; Pilzer and Gozes, 2006a).

Contrary to the aforementioned N-terminal splice variants that were only reported in mammals, IC loops (i.e., IC3) splice products are found in all studied vertebrate species. In the postnatal cerebral cortex of rats, the expression of PAC1-null, hop1, hop, and hop-hop1 dramatically decreases during the first neonatal month suggesting a major role for these isoforms in embryonic development (Shneider et al., 2010). Interestingly, the expression of these isoforms was shown to be gender dependent displaying higher levels in female postnatal brain at least during the first 3 months of development. In the developing retina, the proportion of IC3 PAC1 isoforms changes as development proceeds: PAC1-hop-hop1 transcript demonstrated transient elevation at day P10, while a decrease in PAC1-null and hop along with elevation of PAC1-hop1 level was observed by P20 (Lakk et al., 2012). PAC1-hop1 expression was found in the olfactory bulb, hippocampus, cerebral cortex, cerebellum, and striatum of newborn rats. PAC1-hop2 was present in rat cerebral astrocytes from newborn brains, in neuronal enriched cultures, and in PC12 cells that undergo neuronal differentiation following NGF treatment (Jämen et al., 2002; Onoue et al., 2002; Hashimoto et al., 2003; Ravni et al., 2006; Mustafa et al., 2010).

PAC1-hop was detected at much lower levels in adult tissues and it was therefore speculated to be important for the embryonic development (Shneider et al., 2010; Holighaus et al., 2011). The relative expression of human and rat PAC1 splice variants in the frontal cortex was reported to have the following expression level hierarchy: null > SV1/hop > SV2/hop = SV3/hop-hop (Pisegna and Wank, 1996; Pisegna et al., 1996; Germano et al., 2004; Lutz et al., 2006). PAC1-hop1 was found to be expressed in all neuroendocrine cells, suggesting a fine tuning of PAC1-mediated signaling in the neuroendocrine cells (Mustafa et al., 2010). PAC1-hop1 splice isoform was the major form expressed in the superior cervical ganglia (SCG) sympathetic neurons, which also express PAC1-short (Braas and May, 1999). Zebrafish IC3 splice isoforms are widely expressed in the adult tissues with PAC1-hop1 detected in brain and testis, PAC1-hop2 in the ovary and PAC1-skip variant in the gills (Fradinger et al., 2005). Lastly, although PAC1-TM4 isoform is mainly found in pancreatic β-cells it is also expressed in the cerebral cortex, cerebellum, and brain stem (Chatterjee et al., 1996; Ajpru et al., 2002).

In summary, changes in PAC1 receptor variant expression appear to be most evident during development. The fact that PAC1 splice variants display differential expression patterns in the nervous system suggests that alternative splicing of this gene product plays a role in fine tuning of PAC1 activity in these areas.
REGULATION OF PAC1 SPlicing BY NEURONAL-SPECIFIC RNA-BINDING PROTEINS

The regulation of PAC1 splicing is not well understood. Alternative splicing of pre-mRNA is often regulated by conserved cis-regulatory RNA sequence elements that serve as recognition sites for different splicing factors. These RNA-binding splicing factors differ from the general spliceosome machinery proteins due to the former's ability to either activate or repress the inclusion of alternatively spliced exons, depending on whether the factors' binding site is located upstream, downstream, or inside the exon. Neuronal-specific splicing factors include nova-1/2, Rbfox-1/2, and ELKV2 splicing factors, the neuronal-specific polypyrimidine tract-binding protein (nPTB) as well as a set of heterogeneous nuclear ribonucleoproteins (hnRNP A1,L,F,H1). As the consensus cis-acting binding sequences for the aforementioned splicing factors have been identified, their involvement in regulating the alternative splicing of a given gene by sequence analysis can be predicted. We analyzed the presence of known consensus binding sites for the following RNA-binding proteins: Rbfox-1/2, Nova-1/2 (single and repeatedly organized elements), SC-35, nPTB enhancers and silencers, and CaRRE for Ca\(^{2+}\)/CaM kinase IV recognition sequences. Putative binding sites for neuronal-specific splicing factors in the respective PAC1 genes of human, mouse, and zebrafish are shown in Figure 5.

### A

| Trans-acting Splicing factor | Cis elements | Exons of ADCYAP1R1 genes |
|-----------------------------|--------------|--------------------------|
|                             | Rat          | Mouse                    | Human       | Zebrafish  |
| Rbfox1/2                    | (U)GCAUG     | 4,8,17 (upst) 4,11,15,16 (dnst) 3,4,13,18 (inside) | 4,8 (upst) 4,11,15,16(dnst) 3,4,18 (inside) | 4,8 (upst) 11,15 (dnst) 18 (inside) | 4,18 (upst) 4,15,16,17 (dnst) 98 (inside) |
| CARRE                       | CACY(N)4A    | 17 (upst) 4 (dnst)       | 4,15 (upst) | 15,17 (upst) 11,15 (dnst) | 17,18 (upst) 4,11,15,16 (dnst) |
| Nova1/2                     | YCAY         | 7 (dnst) 8,9,10 (inside) | 7,8,9,17 (upst) 17,18 (dnst) 8,9,10 (inside) | 4,9,13,17 (upst) 6,13 (dnst) 8 (inside) | 9 (upst) 4 (dnst) 9,10,13 (inside) |
| SC-35                       | UGCUGUU      | 13 (upst) 12 (dnst)      | 13 (upst) 12 (dnst) | 18 (upst) 11 (dnst) 13 (inside) |
| hnRNP A1                    | UAGG         | 5,6,10,13,17 (upst) 4,6,9,10,17 (dnst) 10 (inside) | 6,8,9,10,13 (upst) 8,9,16 (dnst) 10 (inside) | 7,8,9,10,13 (upst) 6,9,10,13,16 (dnst) 3 (inside) | 9,11,17 (upst) 8,10 (dnst) 4 (inside) |
| nPTB                        | CUCUCU       | 6,13,14 (upst) 9 (inside) | 5,13,16 (upst) 4 (dnst) | 4,5,10,13,16 (upst) 3 (inside) | 10,15,17 (upst) 9 (dnst) |

| Exons | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|-------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat   | 24 | 06 | 08 | 21 | 42 | 10 | 98 | 13 | 54 | 61 | 70 | 92 | 84 | 94 | 80 | 42 | 89 |
| Mouse | 24 | 06 | 08 | 21 | 42 | 10 | 98 | 13 | 54 | 61 | 70 | 92 | 84 | 94 | 80 | 42 | 89 |
| Human | 24 | 06 | 08 | 21 | 42 | 10 | 98 | 13 | 54 | 61 | 70 | 92 | 84 | 94 | 80 | 42 | 89 |
| Zebras | 24 | 06 | 08 | 21 | 42 | 10 | 98 | 13 | 54 | 61 | 70 | 92 | 84 | 94 | 80 | 42 | 89 |

**FIGURE 5** | Regulation of PAC1 splicing. (A) A chart depicting the predicted binding sites for neuronal-specific RNA-binding proteins that potentially regulate PAC1 gene splicing by binding in proximity to PAC1 exons. Consensus cis-acting binding DNA elements for the respective RNA-binding protein are depicted with respect to their position in the PAC1 genes of rat, mouse, human, and zebrafish.

We analyzed the presence of putative consensus binding sites located within 300 base-pairs upstream (upst) or downstream (dnst) and inside the exons. (B) Schematic representation of the PAC1 gene in which the location of the analyzed cis-acting elements is color-coded as above. Corresponding exons numbers and sizes (bp) are indicated.
Rbfox-1/2 can act either as a splicing enhancer or as an inducer of exon skipping (Zhang et al., 2008). Putative Rbfox-1/2 binding sites located within a short distance downstream of target exons are predicted to induce exon inclusion whereas upstream binding sites are predicted to cause exon skipping. Such Rbfox-1/2 recognition element located within a short distance downstream of hop1 encoding exon has been experimentally validated as a genuine Rbfox-1 binding site (Lee et al., 2009). Our own PAC1 bioinformatic analysis identified a putative Rbfox-1/2 binding element within ~30 nucleotides downstream from conserved exon spanning zebrafish TM7 suggesting that this domain might be regulated by alternative splicing (Figure 5). Rbfox-1/2 motifs are also present in the sequences of all examined species downstream of exon 16 encoding parts of the TM7 domain. Another recognition site is located upstream of exon 4 consistent with a deletion of the exon resulting in the generation of PAC1–very short splice variant (Figure 5). Rbfox-1/2 recognition motif predicts potential deletion of exon 8 that may result in a generation of a soluble PAC1 receptor as in the case of the CRH receptor (Zmilewski and Slominski, 2009, 2010). Rbfox-1/2 binding site is also detected downstream of exon 11, which is known to encode the most hypervariable amino acid sequence among Secretin family GPCRs, as well as part of TM4 domain which undergoes alternative splicing in PAC1–TM4 isoform (Markovic and Grammatopoulos, 2009).

Calcium signaling plays an important role in neuronal development and is involved in the regulation of immediate and long-term neuronal responses to various stimuli such as stressors and hormones (Ghosh et al., 1994; West et al., 2001). Depolarization is known to be critical for modulating the neuronal activity that induces Ca\(^{2+}\)-dependent gene regulation, including alternative splicing. Ca\(^{2+}\)-dependent splicing is mediated by L-type calcium channels and by Ca\(^{2+}\)/calmodulin-dependent protein kinases IV (CaMK IV) (Lee et al., 2007, 2009). The latter was shown to repress splicing of target genes containing specific recognition elements (CaRRE) located within the 3′ splice site or inside the exon. Our own analysis detected additional putative CaRREs that can be responsive to CaMK IV. We predicted single, multiple, and tandemly organized CaRRE repeats upstream of exon 15 and 17 of the zebrafish, human, and mouse PAC1 receptors, suggesting the involvement of CaMK IV in regulating the alternative splicing of these exons. Putative CaRREs are also present proximal to mouse, rat, and zebrafish exon 4 (Figure 5).

Exonic and intronic hnRNPA1 and nPTB cis-elements that are important for activity-dependent splicing in neuronal cells were shown to repress the inclusion of target exons (Allemand et al., 2005; An and Grabowski, 2007; Donev et al., 2007; Resnick et al., 2008; Zheng et al., 2012). Putative hnRNPA1 and nPTB recognition sites are located proximal to exons 4, 5, and 6 consistent with the known deletions of these exons that result in the generation of PAC1–short and very short splice variants. Putative hnRNPA1 recognition motifs are also found near exons 8–10 encoding to IC1, IC2, and EC2 domains (Figure 5). Nova-1/2 regulates target exon inclusion or skipping with broad distribution of binding sites across the gene sequence (Ule et al., 2005; Yano et al., 2010; Norris and Calarco, 2012). Predicted Nova-1/2 recognition elements are found in human and mouse PAC1 and in both paralogs of zebrafish PAC1 gene (1a and 1b). Interestingly, higher frequency of putative splicing-inducing AU-rich and Nova-specific sequences are found in intronic regions upstream of alternative spliced exons characteristic of the Secretin family splicing patterns, e.g., around exon 4, 8, 9, 10 (Zmilewski and Slominski, 2009) as well as exon 17. Exons 4–6 encode sequences covering known N-terminal PAC1 deletion regions (deletions of 7, 21, and 57 amino acids). Exon 17 encodes the last amino acids of the seventh TM domain and the beginning of the IC tail shown to represent the highly conserved exon within the secretin family (Markovic and Grammatopoulos, 2009). Skipping of this exon was not detected in the PAC1 receptor gene, but it has been proposed that such exon skipping in the human CRF1 and PTH1 receptors results in a six TM receptor displaying impaired trafficking (Shyu et al., 1996; Grammatopoulos et al., 1999; Markovic et al., 2008). The rabbit calcitonin receptor is also formed as a result of the skipping of the TM7 domain and displays slightly diminished cAMP activation along with deficiency in IP3 induction (Shyu et al., 1996). Taken together the analysis of potential cis-elements spanning TM7 exons predicts that a PAC1 splice variant containing TM7 skipping may exist in neuronal tissues.

An important question raised in this chapter is whether the aforementioned RNA-binding factors regulate PAC1 splicing in vivo. It has been demonstrated that alternative splicing of the PAC1 receptor is regulated by the Rbfox-1 splicing factor in depolarized neurons. In this case, neuronal depolarization induced CaM-kinase dependent self-splicing of Rbfox-1, leading to the translocation of Rbfox-1/2 into the cytoplasm to the nucleus where Rbfox-1 could mediate the alternative splicing of neuronal-specific target genes, including PAC1. Interestingly, Rbfox-1 mRNA levels were shown to be regulated by the Orthopedia (Otp) homedomain-containing protein. The latter is a hypothalamic-specific transcriptional factor, which plays a role in hypothalamic neuronal-specification during development and in regulation of body homeostasis in the mature zebrafish brain (Acampora et al., 1999; Wang and Lufkin, 2000; Blechman et al., 2007; Ryu et al., 2007; Amir-Zilberstein et al., 2012; Fernandez et al., 2012). The involvement and regulation of other neuronal-specific RNA-binding factors in PAC1 splicing remains to be determined.

**PLEIOTROPIC ROLES OF PAC1 SPlice ISOFORMS IN THE NERVOUS SYSTEM**

The distribution of PAC1 and its ligands PACAP and VIP in a variety of cell types is reminiscent of the pleiotropic functions of PAC1 in development and physiology. PACAP is described in the literature as a hormone, neuropeptide, endocrine peptide, neurotransmitter, and neurotrophic factor. It affects the central nervous system (CNS), cardiovascular system, pituitary, thyroid, and adrenal glands and provides functional activities in the gonads, gastrointestinal tract, and pancreas (Waschek et al., 2000; Dickson and Finlayson, 2009; Vaudry et al., 2009). In the nervous system, PAC1 was shown to affect a variety of hormones and neuropeptides, including stimulation of oxytocin (Jamen et al., 2003) and melatonin (Nakahara et al., 2002) release and de novo
mRNA synthesis of CRH (Nakahara et al., 2002; Amir-Zilberstein et al., 2012), arginine-vasopressin (Murase et al., 1995; Gillard et al., 2006), GnRH (Kanasaki et al., 2009; Winters and Moore, 2011), somatostatin (Kageyama et al., 2007), and MSH (Mounien et al., 2006). This overabundance of PAC1-mediated physiological activities can be made possible through the signaling diversity of its alternatively spliced gene products. Moreover, different expression of PAC1 isoforms is common in neuronal ontogeny. Such differences in the expression of PAC1 splice variants might modulate final outputs of VIP and PACAP activities as neurotransmitters, neurotrophic, or differentiation factors. Examples for the involvement of PAC1 splice isoforms in mediating these activities are described below.

**NEUROGENESIS, NEUROPROTECTION, AND DIFFERENTIATION**

Neural progenitor cells (NPC) and astroglial cells express PAC1-null and PAC1-hop1 variants that mediate both CAMP- and Ca\(^{2+}\)-dependent signaling pathways and induce production of a subset of neurotrophic factors resulting in neuronal proliferation and/or differentiation. PAC1-hop2 variant, detected in astrogenic and neuronal populations, promote neuroprotective function induced by VIP. In another study, VIP was also demonstrated to induce PAC1-hop2-mediated astrocytes neuroprotection against oxidative stress. Astrocytic expression of PAC1-hop2 isoform may therefore play a critical role in the NPC shift toward neuronal or astrocytic differentiation (Ashur-Fabian et al., 1997; Pilzer and Gozes, 2006b).

Expression of PAC1-null and PAC1-hop1 define region-specific neurogenesis in the CNS and peripheral nervous systems (Lu et al., 1998). Both variants are differently expressed in proliferating sympathetic (PAC1-hop1) and cortical precursors (PAC1-null) revealing opposing PACAP-mediated mitogenic regulation – either by stimulating sympathetic neuroblast proliferation or by inhibiting cortical precursor mitosis. Ectopic expression of PAC1-hop1 in cortical neuroblasts may transform the anti-mitotic effect of PACAP into promitotic. This promitotic signaling was shown to involve PLC signaling pathway (Nicot and DiCicco-Bloom, 2001). PAC1-hop1 was also shown to promote sympathetic neurons survival following growth factor withdrawal (May et al., 2010).

In conjunction with the above mentioned, PACAP may possess therapeutic potential for neurodegenerative pathologies, such as Parkinson's and Alzheimer's disease (AD). PACAP is enriched in rat mesencephalic dopaminergic neurons and protects them from neurotoxin-induced death (Reglodi et al., 2004). PACAP was shown to be downregulated in several mouse models for AD as well as in the human temporal cortex of AD patients (Kojro et al., 2006; Rat et al., 2011; Postina, 2012). Amyloidogenic processing of the amyloid precursor protein (APP) to \(\beta\)-peptides is responsible for the development of AD. However, non-amyloidogenic APP processing results in the \(\alpha\)-secretase-dependent cleavage within the \(\beta\)-peptide region, preventing AD pathology. Continual PACAP and PAC1 activation resulted also in a feed-forward autocrine elevation of both PACAP and PAC1 in mice that may further facilitate non-amyloidogenic APP cleavage. \(\alpha\)-secretase activation was shown to be regulated by ERK1 and ERK 2 and PI-3 kinase, suggesting that PAC1-hop1 is the most efficient isoform with regard to the activation of these downstream PLC effectors (Kojro et al., 2006; Rat et al., 2011; Postina, 2012). It remains to be determined whether specific PAC1 splice variants are involved in these neuroprotective activities.

**NEUROSECRETION AND NEUROTRANSMISSION**

Pituitary AC-activating polypeptide was shown to elicit catecholamine synthesis and release. Expression of PAC1-hop1 in bovine chromaffin NG108-15 cell line, which lacks endogenous PAC1 receptors, induces the release of norepinephrine via a Ca\(^{2+}\)-influx-dependent mechanism (Mustafa et al., 2007). Transfected PAC1-hop1 triggers sustained catecholamine secretion by regulating Ca\(^{2+}\) levels through both ER and EC Ca\(^{2+}\) channels (Mustafa et al., 2010; Smith and Eiden, 2012). Moreover, acute and long-term met-enkephalin secretion and enkephalin biosynthesis were attributed to bovine chromaffin cells upon PAC1-hop1-mediated activation of L-type Ca\(^{2+}\) channels. This implies a role of hop1 splice cassette in regulating neuroendocrine secretion. SCG sympathetic neurons were shown to predominantly express the PAC1-hop1 splice isoform and PACAP stimulates neuropeptide Y release in these neurons via a mechanism involving both AC and PLC\(\beta\) (Braas and May, 1999).

**ROLE OF PAC1 SPLICE ISOFORMS IN BODY HOMEOSTASIS**

PAC1 is implicated in the regulation of homeostatic processes, including food and liquid consumption (Nomura et al., 1997; Mounien et al., 2006, 2009), sleep (Hannibal and Fahrenkrug, 2004), stress (Pilzer and Gozes, 2006b; Amir-Zilberstein et al., 2012), locomotion (Vaudry et al., 2000), memory and learning activities (Dong et al., 2010; Andero and Ressler, 2012; Holighaus et al., 2012), and circadian functions (Aipru et al., 2002; Hannibal and Fahrenkrug, 2004). Recent studies have indicated that at least some of these activities are modulated by alternative splicing of PAC1 (Aipru et al., 2002; Hannibal and Fahrenkrug, 2004; Pilzer and Gozes, 2006b; Holighaus et al., 2011, 2012; Amir-Zilberstein et al., 2012).

Pituitary AC-activating polypeptide/PAC1 signaling was recently implicated in abnormal stress responses underlying post-traumatic stress disorder (PTSD) pathology (Ressler et al., 2011; Andero and Ressler, 2012; Hauger et al., 2012). PACAP38 levels in females were strongly associated with PTSD symptoms. Ressler et al. and May et al. (2010) found that a single nucleotide polymorphism (SNP), rs2267735 in the PAC1 gene is correlated with PTSD in a gender-specific estrogen-dependent manner. This SNP, which resides in the putative estrogen response element within PAC1’s promoter/enhancer is associated with sex-dependent PTSD, fear discrimination, PAC1 mRNA expression, and methylation of PAC1. Using mouse models, these authors showed that PAC1 mRNA was induced by fear conditioning or estrogen hormone replacement in the bed nucleus of stria terminals (BNST), which is a component of the extended amygdala involved in fear- and anxiety-like responses.

In connection to the above, steroid-induced changes in PAC1 splice isoforms were demonstrated in the case of PAC1-hop2 (Apostolakis et al., 2005). PAC1-hop2 and the N-terminal PAC1-hop1 splice isoforms were demonstrated in the case of PAC1-hop2 and the N-terminal PAC1 in the midbrain, which is a component of the extended amygdala involved in fear and anxiety-like responses.

www.frontiersin.org
treatment. The ratio of PAC1-hop2 mRNA to other PAC1 variants in VMN depends on steroid application, implying its importance for cumulative PAC1 isoforms expression and hence signaling properties. PACAP-induced sexual/mating behavior in female rats was dependent on progesterone receptor in the VMN. Estradiol stimulates synthesis of progesterone, which in turn facilitates PACAP synthesis and activation of PAC1-short and -hop2 signaling critical for the induction of animal sexual receptivity.

PAC1 signaling is known to be required for physiological stress response as activation of PAC1 by PACAP is required for stress-induced CRH transcription in vivo and in vitro (Agarwal et al., 2005; Kageyama et al., 2007; Hammack et al., 2010b; Stroth and Eiden, 2010; Tsukiyama et al., 2011). The above studies suggest that PAC1 splice variants and their relative expression ratio might be involved in the regulation of body homeostasis including physiological responses to stressor challenges. A recent study performed in our lab, employed various stress paradigms in mouse and zebrafish to demonstrate that activation and termination of CRH transcription caused by stressful stimuli is regulated by an interrelationship of PAC1-null and hop1 isoforms (Amir-Zilberstein et al., 2012). Thus, the generation of PAC1-hop1 by alternative splicing leads to the termination of CRH transcription, normal activation of the hypothalamic-pituitary-adrenal axis, and adaptive anxiety-like behavior (Amir-Zilberstein et al., 2012). We therefore suggested that alternative splicing of the hop1-cassette serves as an ON/OFF stress switch (Figure 6).

PAC1 rs2267735 gene polymorphism is also associated with increased dark-enhanced startle (DES) in adult females but not males with PTSD (Ressler et al., 2011). Moreover, children of abused mothers show elevated DES and the same PAC1 gene polymorphism associated with PTSD risk in adult females is also associated with increased DES in these children (Jovanovic et al., 2011, 2012). Notably, zebrafish larvae show a strong aversion to the dark side of a two-compartment light/dark arena and this place preference can be mitigated by anxiolytic drugs, such as Diazepam, indicating that this assay measures an anxiety-like behavior (Steenbergen et al., 2011; Schnorr et al., 2012). We found that during the recovery phase that follows a stressful challenge (osmotic shock), wild type larvae decrease their dark-avoidance time, a phenotype indicative of decreased stress-related anxiety, while larvae with depleted PAC1a-hop1 display delayed dark-avoidance recovery (Amir-Zilberstein et al., 2012). Thus, the delayed behavioral response of PAC1a-hop1-depleted embryos correlates with their respective failure to terminate crh and cortisol levels following stressors.

CONCLUSION

Alternative splicing is a major gene regulatory process involving cis- and trans-acting factors. PAC1 signaling controls a variety of cellular and physiological responses, such as differentiation, proliferation, cell cycle regulation, neurotransmitter, and hormone release and adaptation to stressful challenges. The PAC1 gene encompasses a relatively long genomic region, which consists of up to 18 exons and contains many putative splicing factors recognition sites that might be activated during different phases of neuronal activation. PAC1 receptor signaling can be fine-tuned by the generation of a set of alternatively spliced variants produced in a spatio-temporal manner. Splicing-dependent alterations in PAC1 protein domains modify its ligand binding and signaling properties leading to a range of cellular activities. Although the physiological function(s) of the vast majority of the alternatively spliced PAC1 gene products is still unknown, recent studies have implicated certain PAC1 splice variants in the regulation of homeostatic processes such as adaptation to stressful challenges. In view of the recent association of PAC1 with PTSD risk, the regulation of PAC1 splicing and its underlying physiological outcomes might prove to be relevant to the etiology of some neurological and psychiatric disorders.

ACKNOWLEDGMENTS

We thank Shifra Ben-Or for PAC1 gene structure and phylogenetic analyses and Danielle Sabah-Israel, Jacob Biran, and Michael Glicksberg for comments on the manuscript. The research in the Levkowitz lab is supported by the Simons Foundation Autism Research Initiative (SFARI); Israel Science Foundation; Kirk Center for Childhood Cancer and Immunological Disorders; The Kreuter Institute and Estate of Lore Lennon.
Abu-Hamdan, M. D., Drescher, M. J., Ramakrishnan, N. A., Khan, K. M., Toma, V. S., Hatfield, J. S., et al. (2006). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.

Braas, K. M., and May, V. (1999). Pituitary adenyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. *Neuroscience* 140, 147–161.

Acampora, D., Postiglione, M. P., Avanzato, G., Halvorson, L. M., and Acampora, D., Postiglione, M. P., Avan-. Allemand, E., Guil, S., Myers, M., Ajpru, S., McArthur, A. J., Piggins, H. (2012). Blechman and Levkowitz PAC1 splicing in the nervous system.

Neuroendocrine system. *Neurosci. Lett.* 523, 62–67.
amyloid precursor protein isoforms. 

*J. Biol. Chem.* 284, 15325–15338.

Fradinger, E. A., Tello, J. A., Rivier, J. E., and Sherwood, N. M. (2005). Characterization of four receptor cDNAs: PAC1, VPAC1, a partial PAC1 and a partial GHRH in zebrafish. *Mol. Cell. Endocrinol.* 231, 49–63.

Frooninckx, L., Van Rompay, L., Temmerman, L., Van Sinay, E., Beets, I., Janssen, T., et al. (2012). Neuropeptidergic CRs in C. elegans. *Front. Endocrinol.* 3:167. doi:10.3389/fendo.2012.00167

Furness, S. G., Wootten, D., Christopulos, A., and Sexton, P. M. (2012). Consequences of splice variation on Secretin family G protein-coupled receptor function. *Br. J. Pharmacol.* 166, 98–109.

Gerlin, M. J., and Eiden, L. E. (2007). Regulation of PC12 cell differentiation by cAMP signaling to ERK independent of PKA: do all the connections add up? *Sci. STKE* 2007, e15.

Germaino, P. M., Le, S. V., Oh, D. S., Fan, R., Lieu, S., Siau, A., et al. (2004). Differential coupling of the PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2+ does not activate tumor proliferation. *J. Mol. Neurosci.* 22, 83–92.

Germaino, P. M., Lieu, S. N., Xue, J., Cooke, H. J., Christofi, E. L., Yu, Y., et al. (2009). PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells. *J. Mol. Neurosci.* 39, 591–601.

Ghosh, A., Ginty, D. D., Bading, H., and Greenberg, M. E. (1994). Calcium regulation of gene-expression in neuronal cells. *J. Neurobiol.* 25, 294–303.

Gillard, E. R., Leon-Olea, M., Macio-Ramirez, S., Coburn, C. G., Sanchez-Islas, E., De Leon, A., et al. (2006). A novel role for endogenous pituitary adenylyl cyclase activating polypeptide in the magnocellular neuroendocrine system. *Endocrinology* 147, 791–803.

Girard, B. M., Keller, E. T., Schutz, K. C., May, V. Y., and Braas, K. M. (2004). Pituitary adenylyl cyclase activating polypeptide and PAC1 receptor signaling increase Homer 1a expression in central and peripheral neurons. *Regul. Pept.* 123, 107–116.

Gomariz, R. P., Juarranz, Y., Abad, C., Grimaldi, M., and Cavallaro, S. (1999). Functional and molecular diversity of PACAP receptors mediating neuroendocrine responses for PTSD pathophysiology and non-peptide ligands: a tribute to PACAP receptors: drug targets, and peptide and antagonist development. *Front. Pharmacol.* 3:167.

Jaillon, O., Bouhouche, K., Gout, J. F., Hannibal, J., and Fahrenkrug, J. (2004). Target areas innervated by PACAP-immunoreactive retinal ganglion cells. *Cell Tissue Res.* 316, 99–113.

Hansson, E., Westerlund, A., Bjorklund, U., and Ronnback, L. (2009). PACAP regulates 5-HT, histamine, and ATP-evoked Ca2+ transients in astrocytes. *Neuroreport* 20, 957–962.

Harikumar, K. R., Morfis, M. M., Sexton, P. M., and Miller, L. J. (2008). Pattern of intra-family heterooligomerization involving the G-protein-coupled secretin receptor. *J. Mol. Neurosci.* 36, 279–285.

Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisejna, J. R., et al. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenyl cyclase-activating polypeptide: IUPHAR review 1. *Br. J. Pharmacol.* 166, 14–17.

Hashimoto, H., Kunugi, A., Arakawa, N., Shintani, N., Fujita, T., Kasai, A., et al. (2003). Possible involvement of a cyclic AMP-dependent mechanism in PACAP-induced proliferation and ERK activation in astrocytes. *Biochem. Biophys. Res. Commun.* 311, 337–343.

Hauger, R. L., Olivares-Reyes, J. A., Dautzenberg, F. M., Lohr, J. B., Braun, S., and Oakley, R. H. (2012). Molecular and cellular signaling targets of PISD and pituitary adenyl cyclase activating peptide (PACAP) receptor. *Biochim. Biophys. Acta.* 1826, 702–714.

Holighaus, Y., Mustafa, T., and Eiden, L. E. (2011). PAC1/3H10 null and hip receptors mediate differential signaling through cyclic AMP and calcium leading to splice variant-specific gene induction in neural cells. *Peptides* 32, 1647–1655.

Holighaus, Y., Weibe, E., and Eiden, L. E. (2012). STC1 induction by PACAP is mediated through cAMP and ERK1/2 but not PKA in cultured cortical neurons. *J. Mol. Neurosci.* 46, 75–87.
receptor (ADCA/P1R) genotype is associated with dark-enhanced startle in children. Mol. Psychia-
try, doi:10.1038/mp.2012.98. [Epub ahead of print].
Jovanovic, T., Smith, A., Kamelwala, A., Poole, J., Samples, T., Nordholm, S. D., et al. (2011). Physiological mark-
ers of anxiety are increased in chil-
dren of abused mothers. J. Child.
Psychol. Psychiatry 52, 844–852.
Kageyama, K., Hanada, K., Iwasaki, Y., Sakahira, S., Nagawara, T., Kascovk, J., et al. (2007). Pituitary adenylate
cycle-activating polypeptide stimulates corticotropin-releasing factor, vasopressin and interleukin-6 gene
transcription in hypothalamic 4B cells. J. Endocrinol. 195, 199–211.
Kanasaki, H., Mutiara, S., Oride, A.,
Kojro, E., Postina, R., Buro, C.,
Lee, J. A., Xing, Y., Nguyen, D., Xie,
doi:10.1371/journal.pbio.0050040
Mol. Psychiatry 17, 1–27.
Masmoudi, O., Gandolfo, P., Leprince, I., Vaudry, D., Pelletier, G.,
Fourrier, A., et al. (2006). PACAP stimulates biosynthesis and release of endopeptidases from rat astrocytes.
Ann. N. Y. Acad. Sci. 1070, 411–416.
Maturana, A., Van Haasteren, G., Piu,
L., Castelbou, C., Demaurex, N., and
Schlegel, W. (2002). Spontaneous calcium oscillations control c-fos transcription via the serum response
element in neuroendocrine cells. J. Biol. Chem. 277, 39713–39721.
Magalhaes, A. C., Dunn, H., and Fer-
ger, S. S. (2012). Regulation
of GPCR activity, trafficking and
localization by GPCR-interacting
proteins, major players of GPCR function. Adv. Pharmacol. 62, 349–380.
McCulloch, D. A., MacKenzie, C.,
Schutz, K. C., Doraz, K., and
Braas, K. M. (2010). Pituitary adenylate
cycle-activating polypeptide (PACAP)/PAC1R receptor activa-
tion coordinates multiple neu-
rotrophic signaling pathways: Akt
activation through phosphatidy-
linositol 3-kinase gamma and vesicle
endocytosis for neuronal survival. J.
Biol. Chem. 285, 9749–9761.
Mcculloch, D. A., Lutz, E. M., Johnson,
M. S., Robertson, D. N., MacKen-
ze, C. J., Holland, P. J., I., et al. (2011).
ADP-ribosylation factor-dependent phospholipase D activation by VPAC
receptors and a PAC(1) receptor
splice variant. Mol. Pharmacol. 80, 1523–1532.
Mcculloch, D. A., MacKenzie, C. J.,
Johnson, M. S., Robertson, D. N.,
Holland, P. I., Ronaldson, E.,
et al. (2002). Additional signals from
VPAC/PACAP family receptors. Bio-
chem. Soc. Trans. 30, 441–446.
Mei, Y. A., Vaudry, D., Basile, M.,
Castel, H., Fourrier, A., Vaudry,
H., et al. (2004). PACAP inhibits delayed rectifier potassium current via a CAMP/PKA transduction path-
way: evidence for the involvement of
FK in the anti-apoptotic action of
PACAP. Eur. J. Neurosci. 19,
1446–1458.
Milligan, G., and Kostenis, E. (2006).
Heterotrimetric G-proteins: a short
history. Br. J. Pharmacol. 147(Suppl. 1),
546–555.
Miyata, A., 17
Miyata, A., Arimura, A., Dahl, R. R.,
Minamino, N., Uehara, A., Jiang, L.,
et al. (1989). Isolation of a novel 38
residue-hypothalamic polypeptide which stimulates adenylate cyclase in
pituitary cells. Biochem. Biophys. Res.
Commun. 164, 567–574.
Miruno, N., and Itoh, H. (2009). Func-
tions and regulatory mechanisms of
Gq-signaling pathways. Neurognalns
17, 42–54.
Mohlin, L., Pollak, E., Boros, A., Shioda,
S., Nakajo, S., Tamas, A., et al. (2008).
PAC1 receptor localization in a model nervous system: light and electron microscopic immunocyto-
chemistry on the earthworm ventral nerve cord ganglia. Regul. Pept. 145,
96–104.
Monaghan, T. K., Pou, C., MacKenzie,
C. J., Plevin, R., and Lutz, E. M. (2008).
Neurotrophic actions of PACAP-38
and LIF on human neuroblastoma
SH-SYSY cells. J. Mol. Neurosci. 36,
45–56.
Morris, M., Christopoulos, A., and Sex-
ton, P. M. (2003). RAMPs: 5 years on,
where to now? Trends Pharmacol. Sci.
24, 596–601.
Mounien, L., Biset, P., Boutelet, I.,
Gourcerol, G., Fourrier, A., Vaudry,
H., et al. (2006). Pituitary adenylate
cycle-activating polypeptide directly modulates the activity of
proopiomelanocortin neurons in the rat arcuate nucleus. Neurosci-
est. 143, 155–163.
Mustafa, T., Do Rego, J. C., Biset,
P., Boutelet, I., Gourcerol, G.,
Fourrier, A., et al. (2009). Pitu-
itary adenylate cyclase-activating polypeptide inhibits food intake in
mice through activation of the hypo-
thalamus melanocortin system. Neu-
rpsychopharmacology 34, 424–435.
Murase, T., Kondo, K., Arima, H.,
Iwasaki, Y., Ito, M., Miura, Y.,
et al. (1995). The expression of pitu-
itary adenylate cyclase-activating polypeptide in rat brain: possible role of endogenous
PACAP in vasopressin release. Neu-
rasci. Lett. 185, 103–106.
Mustafa, T., Grimaldi, M., and Eiden,
L. E. (2007). The hop cassette of the
PAC1 receptor confers coupling to
Ca2+-evoked requirement for pitu-
itary adenylate cyclase-activating
polypeptide-evoked neurotranscretion. J. Biol. Chem. 282, 8079–8091.
Mustafa, T., Walsh, J., Grimaldi, M.,
and Eiden, L. E. (2010). PAC1
receptor activation facilitates cat-
echolamine secretion selectively
through 2-APB-sensitive Ca(2+)-
channels in PC12 cells. Cell. Signal.
22, 1442–1456.
Nakahara, K., Ake, Y., Murakami,
T., Shiota, K., and Murakami, N.
(2002). Pituitary adenylate cyclase-
activating polypeptide (PACAP) is
involved in melanin release via the
specific receptor PCAP-r1, but not

www.frontiersin.org
May 2013 | Volume 4 | Article 55 | 17
Bleichman and Levkowitz PAC1 splicing in the nervous system
in the circadian oscillator, in chick pineal cells. Brain Res. 939, 19–25.
Nicot, A., and DiCarlo-Bloom, E. (2001). Regulation of neuroblast mitosis is determined by PACAP receptor isoform expression. Proc. Natl. Acad. Sci. U.S.A. 98, 4758–4763.
Nishimoto, M., Furuta, A., Aoki, S., Kudo, Y., Miyakawa, H., and Wada, K. (2007). PACAP/PAC1 autocrine system promotes proliferation and astrogenesis in neural progenitor cells. Glia 55, 317–327.
Nomura, M., Ueta, Y., Larsen, P. J., Hannibal, J., Serino, R., Kabashima, N., et al. (1997). Water deprivation increases the expression of pituitary adenylate cyclase-activating polypeptide gene in the rat subfornical organ. Endocrinology 138, 4096–4100.
Nordstrom, K. J., Lagerstrom, M. C., Waller, L. M., Fredriksson, R., and Schioth, H. B. (2009). The Secretin GPCRs descended from the family of Adhesion GPCRs. Mol. Biol. Evol. 26, 71–84.
Norris, A. D., and Calarco, J. A. (2012). Emerging roles of alternative pre-mRNA splicing regulation in neuronal development and function. Front. Neurosci. 6:122. doi:10.3389/fnins.2012.00122
Oldham, W. M., and Hamm, H. E. (2008). Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 9, 60–71.
Onoue, S., Endo, K., Yajima, T., and Kashimoto, K. (2002). Pituitary adenylate cyclase activating polypeptide regulates the basal production of nitric oxide in PC12 cells. Life Sci. 71, 205–214.
Pantalone, C., Brabet, P., Bilanges, B., Dumas, A., Houssami, S., Spengler, D., et al. (1996). Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J. Biol. Chem. 271, 22146–22151.
Parsons, R. J., Rossignol, T. M., Calupca, J. M., Seasholtz, T. M., Mitchell, R., and Lutz, E. M. (2002). Specific interaction between the hop1 intracellular loop 3 domain of the human PAC1 receptor and ARF. Regul. Pept. 109, 193–198.
Pei, J., Wink, S. A., and Wurk, C. S. (1996). Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase-activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 271, 17267–17274.
Postina, R. (2012). Activation of alpha-secretase cleavage. J. Neurochem. 100 (Suppl. 1), 46–54.
Pugh, P. C., Jayakar, S. S., and Margiotta, J. F. (2010). PACAP/PAC1(R) signal modulating acetylcholine release at neuronal nicotinic synapses. Mol. Cell. Neurosci. 43, 244–257.
Pugh, P. C., and Margiotta, J. F. (2006). PACAP support of neuronal survival requires MAPK- and activity-generated signals. Mol. Cell. Neurosci. 31, 586–595.
Rat, D., Schmitt, U., Tippmann, P., Dewachter, I., Thenuis, C., Wiczerzak, E., et al. (2011). Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice. PASEB J. 7, 3208–3218.
Ravni, A., Bourgault, S., Lebon, A., Chan, P., Galas, L., Fournier, A., et al. (2006). The neurotrophic effects of PACAP in PC12 cells: control by multiple transduction pathways. J. Neurochem. 98, 321–329.
Regoli, D., Lubich, A., Tamas, A., Szalontay, L., and Lengvari, I. (2004). Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson’s disease. Behav. Brain Res. 151, 303–312.
Resnick, M., Segall, A., Roczio-Kolarro, G., Lupowitz, Z., and Zisapel, N. (2008). Alternative splicing of neuroexins: a role for neuronal polyprideintract binding protein. Neurosci. Lett. 439, 235–240.
Ressler, K. J., Mercer, K. B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., et al. (2011). Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470, 492–497.
Ritter, S. L., and Hall, R. A. (2009). Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10, 819–830.
Rondel, D., Robertson, D. N., Johnson, M. S., Holland, P. J., Mitchell, R., and Lutz, E. M. (2002). Specific interaction between the hop1 intracellular loop 3 domain of the human PAC1 receptor and ARF. Regul. Pept. 109, 193–198.
Ryu, S., Maehler, J., Acampora, D., Holzschuh, J., Erhardt, S., Omodei, D., et al. (2007). Orthopia homeodomain protein is essential for diencaphalic dopaminergic neuron development. Curr. Biol. 17, 873–880.
Sah, V. P., Seasholtz, T. M., Sagi, S. A., and Brown, J. H. (2000). The role of Rho in G protein-coupled receptor signal transduction. Annu. Rev. Pharmacol. Toxicol. 40, 459–489.
Schneid, S. J., Steenbergen, P. J., Richardson, M. K., and Champagne, D. L. (2012). Measuring thigmotaxis in larval zebrafish. Behav. Brain Res. 228, 367–374.
Shi, G. X., Jin, L., and Andrews, D. A. (2006). Src-dependent TrkA activation is required for pituitary adenylate cyclase-activating polypeptide 38-mediated Rit activation and neuronal differentiation. Mol. Cell. Biol. 21, 1597–1608.
Shi, G. X., Rehmann, H., and Andrews, D. A. (2006). A novel cylic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiation. Mol. Cell. Biol. 26, 9136–9147.
Shioda, S., Yada, T., and Nakajo, S. (1998). PACAP increases cytosolic calcium in vasopressin neurons: synergism with noradrenaline. Ann. N. Y. Acad. Sci. 865, 427–430.
Shiro, S., Yada, T., Nakajo, S., Nakaya, Y., and Asimura, A. (1997). Pituitary adenylate cyclase-activating polypeptide (PACAP): a novel regulator of vasopressin-containing neurons. Brain Res. 765, 81–90.
Shneider, Y., Shtrauss, Y., Yadid, G., and Pinhasov, A. (2010). Differential expression of PACAP receptors in postinnatal rat brain. Neuropeptides 44, 509–514.
Shyu, J. F., Inoue, D., Baron, R., and Horne, W. C. (1996). The depletion of 14 amino acids in the seventh transmembrane domain of a naturally occurring calcitonin receptor isoform alters ligand binding and selectively abolishes coupling to phospholipase C. J. Biol. Chem. 271, 3127–3134.
Simon, M. L., Strathmann, M. P., and Gautham, N. (1991). Diversity of G proteins in signal transduction. Science 252, 802–808.
Smith, C. B., and Eiden, L. E. (2012). Is PACAP the major neurotransmitter for stress transduction at the adrenomedullary synapse? J. Mol. Neurosci. 48, 403–412.
Spengler, D., Waeb, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeberg, P. H., et al. (1993). Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170–175.
Steenbergen, P. J., Richardson, M. K., and Champagne, D. L. (2011). Patterns of avoidance behaviours in the light/dark preference test in young juvenile zebrafish: a pharmacological study. Behav. Brain Res. 222, 15–25.
Stor, J., De Bock, F., Guirrmeau, N. C., Janssens, A., Barriere-Lemaire, S., Bos, J. L., et al. (2007). Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+ dependent K+ channels in cerebellar neurons. Proc. Natl. Acad. Sci. U.S.A. 104, 2519–2524.
Stroth, N., and Eiden, L. E. (2010). Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience 165, 1025–1036.
Stumm, R., Kolodziej, A., Prinz, V., Endres, M., Wu, D. E., and Hollf, V. (2007). Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J. Neurochem. 103, 669–675.
Sun, S., Zhang, Z., Fregoso, O., and Krainer, A. R. (2012). Mechanisms of activation and repression by the alternative splicing factors BF10X/1/2. RNA 18, 274–283.
Blechman and Levkowitz

PAC1 splicing in the nervous system

Tanaka, K., Shibuya, I., Harayama, N., Nomura, M., Kabashima, N., Ueta, Y., et al. (1997). Pituitary adenylate cyclase-activating polypeptide causes Ca2+ release from ryanodine/caffeine stores through a novel pathway independent of both inositol trisphosphates and cyclic AMP in bovine adrenal medullary cells. J. Neurochem. 70, 1652–1661.

Taupenot, L., Mahata, M., Mahata, S. K., and O’Connor, D. T. (1999). Time-dependent effects of the neuropetide PACAP on catecholamine secretion: stimulation and desensitization. Hypertension 34, 1152–1162.

Tsuchiyama, N., Saida, Y., Kakuwa, M., Shintani, N., Hayata, A., Morita, Y., et al. (2011). PACAP centrally mediates emotional stress-induced corticosterone responses in mice. Stress 14, 368–375.

Ule, J., Ule, A., Spencer, J., Williams, A., Hu, J. S., Cline, M., et al. (2005). Nova regulates brain-specific splicing to shape the synapse. Nat. Genet. 37, 844–852.

Ushiyama, M., Ikeda, R., Sugawara, H., Yoshida, M., Mori, K., Kangawa, K., et al. (2007). Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third intracellular loop. Mol. Pharmacol. 72, 103–111.

Ushiyama, M., Ikeda, R., Yoshida, M., Mori, K., Kangawa, K., Sugawara, H., et al. (2010). Alternative splicing of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor contributes to function of PACAP-27. J. Mol. Neurosci. 42, 341–348.

Vallejo, M. (2009). PACAP signaling to DREAM: a cAMP-dependent pathway that regulates cortical astrogenesis. Mol. Neurobiol. 39, 90–100.

Vaudry, D., Basille, M., Morel, A. F., Aubert, N., Botia, B., Allais, A., et al. (2007). Neurotrophic effects of PACAP in the cerebellar cortex. J. Mol. Neurosci. 33, 312–312.

Vaudry, D., Faluill-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., et al. (2009). Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283–357.

Vaudry, D., Faluill-Morel, A., Leulliet, S., Vaudry, H., and Gonzalez, B. J. (2003). Regulators of cerebellar granule cell development act through specific signaling pathways. Science 300, 1532–1534.

Vaudry, D., Gonzalez, B. J., Basille, M., Pamantung, T. F., Fournier, A., and Vaudry, H. (2000). PACAP acts as a neurotrophic factor during histogenesis of the rat cerebellar cortex. Ann. N. Y. Acad. Sci. 921, 293–299.

Villalta, M., Bockaert, J., and Journot, L. (1997). Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J. Neurosci. 17, 83–90.

Wang, W., and Luikin, T. (2008). The murine Opr homobox gene plays an essential role in the specification of neuronal cell lineages in the developing hypothalamus. Dev. Biol. 227, 432–449.

Waschek, J. A. (2003). Multiple actions of pituitary adenyl cyclase activating peptide in nervous system development and regeneration (vol 24, pg 14, 2002). Dev. Neurosci. 25, 393–393.

Waschek, J. A., DiCicco-Bloom, E. M., Lelievre, V., Zhou, X., and Hu, Z. (2000). PACAP action in nervous system development, regeneration, and neuroblastoma cell proliferation. Ann. N. Y. Acad. Sci. 921, 129–136.

Watkins, H. A., Au, M., and Hay, D. L. (2012). The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development. Drug Discov. Today 17, 1006–1014.

Wei, X., Martin, S. C., Heinrich, G., and Mosjøs, S. (1998). Cloning and functional characterization of PACAP specific receptors in zebrafish. Ann. N. Y. Acad. Sci. 865, 45–48.

West, A. E., Chen, W. G., Dalva, M. B., Dolmetsch, R. E., Kornhauser, J. M., Shaywitz, A. J., et al. (2001). Calcium regulation of neuronal gene expression. Proc. Natl. Acad. Sci. U.S.A. 98, 11024–11031.

Winters, S. J., and Moore, J. P. (2011). PACAP, an autocrine/paracrine regulator of gonadotrophs. Biol. Reprod. 84, 844–850.

Xue, C., Houyh, Y. P., and Heitman, J. (2008). Magnificent seven: roles of G protein-coupled receptors in extracellular sensing in fungi. FEMS Microbiol. Rev. 32, 1010–1032.

Yano, M., Hayakawa-Yano, Y., Mele, A., and Darnell, R. B. (2010). Nova2 regulates neuronal migration through an RNA switch in disabled-1 signaling. Neuron 66, 848–858.

Yeo, G. W., Xu, X., Liang, T. Y., Muetri, A. R., Carson, C. T., Coudal, N. G., et al. (2007). Alternative splicing events identified in human embryonic stem cells and neural progenitors. PLoS Comput. Biol. 3:e196. doi:10.1371/journal.pcbi.0030196

Zhang, C., Zhang, Z., Castle, J., Sun, S., Johnson, J., Krainer, A. R., et al. (2008). Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. Genes Dev. 22, 2550–2563.

Zhang, X., and Eggert, U. S. (2013). Non-traditional roles of G protein-coupled receptors in basic cell biology. Mol. Biosyst. 9, 586–595.

Zheng, S., Gray, E. E., Chawla, G., Porse, B. T., O’Dell, T. J., and Black, D. L. (2012). PSD-95 is posttranslationally repressed during early neural development by PTBP1 and PTBP2. Nat. Neurosci. 15, 381–388.

Zmijewski, M. A., and Slominski, A. T. (2009). CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J. Cell. Physiol. 218, 593–602.

Zmijewski, M. A., and Slominski, A. T. (2010). Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim. Pol. 57, 1–13.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 25 November 2012; accepted: 24 April 2013; published online: 21 May 2013.

Citation: Blechman J and Levkowitz G (2013) Alternative splicing of the pituitary adenylate cyclase-activating polypeptide receptor PAC1: mechanisms of fine tuning of brain activity. Front. Endocrinol. 4:55. doi: 10.3389/fendo.2013.00055

This article was submitted to Frontiers in Neuroendocrine Science, a specialty of Frontiers in Endocrinology. Copyright © 2013 Blechman and Levkowitz. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.